NCT06335927View on ClinicalTrials.gov

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 10, 2025

Study Completion Date

May 10, 2026

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

HAIC-GEMOX+Cadonilimab+Regorafenib

HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER